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Activation of mammalian target of rapamycin
mediates rat pain-related responses induced by
BmK I, a sodium channel-specific modulator
Feng Jiang1†, Xue-Yan Pang2†, Qing-Shan Niu1, Li-Ming Hua1, Ming Cheng1 and Yong-Hua Ji1*
Abstract
The mammalian target of rapamycin (mTOR) is known to regulate cell proliferation and growth by controlling protein
translation. Recently, it has been shown that mTOR signaling pathway is involved in long-term synaptic plasticity.
However, the role of mTOR under different pain conditions is less clear. In this study, the spatiotemporal activation of
mTOR that contributes to pain-related behaviors was investigated using a novel animal inflammatory pain model
induced by BmK I, a sodium channel-specific modulator purified from scorpion venom. In this study, intraplantar
injections of BmK I were found to induce the activation of mTOR, p70 ribosomal S6 protein kinase (p70 S6K) and
eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) in rat L5-L6 spinal neurons. In the spinal cord, mTOR, p70 S6K
and 4E-BP1 were observed to be activated in the ipsilateral and contralateral regions, peaking at 1–2 h and recovery at
24 h post-intraplantar (i.pl.) BmK I administration. In addition, intrathecal (i.t.) injection of rapamycin – a specific inhibitor
of mTOR – was observed to result in the reduction of spontaneous pain responses and the attenuation of unilateral
thermal and bilateral mechanical hypersensitivity elicited by BmK I. Thus, these results indicate that the mTOR signaling
pathway is mobilized in the induction and maintenance of pain-activated hypersensitivity.
Keywords: BmK I, mTOR, p70S6K, 4E-BP1, Rapamycin, Pain, Mirror-image mechanical hypersensitivity
Introduction
Scorpion envenomation is known to release neurotoxins
that induce long term pain sensation, edema and hyper-
sensitivity [1-3]. Various neurotoxic polypeptides have
been purified from the venom of the scorpion Buthus
martensi Karsch (BmK) and have been shown to be spe-
cific modulators of the voltage gated sodium channel
(VGSC) [4-9]. Among them, BmK I (receptor site 3
VGSC-specific modulator) has been demonstrated to be
the primary contributor of envenomation-associated pain
[10,11] as a result of its ability to increase persistent cur-
rents of tetrodotoxin-resistant (TTX-R) sodium channels
and by delaying the inactivation phase of VGSCs [10]. As
a novel pain model, many clinical pain symptoms, such as
persistent spontaneous responses, thermal hypersensitivity
and bilateral (mirror-image) mechanical hypersensitivity,
could be well mimicked by intraplantarly (i.pl.) injection
of BmK I in rat left hind paw. Interestingly, rat injected
with BmK I always rolls on the floor suddenly, strongly
shakes and bites the injected paw, and sometimes accom-
panied by shriek for several seconds. The unique and ex-
treme spontaneous nociceptive behavior was defined as
paroxysmal pain-like behavior [10]. Significant changes in
spinal neuronal activities [12,13] were observed to be asso-
ciated with BmK I-induced pain. However, it is still
unclear how downstream intracellular activities in the cen-
tral nervous system (CNS) amplify responses to BmK I-
induced nociception.
The mammalian target of rapamycin (mTOR), a serine/
threonine protein kinase, has been regarded as the hub of
the intracellular signaling network as various types of sig-
nals converge on mTOR, thereby controlling the intracel-
lular processes governing homeostasis [14,15]. Activated
mTOR can then phosphorylate downstream molecules
such as p70 ribosomal S6 protein kinase (p70 S6K) on two
residues [16,17] which can then activate S6 ribosomal pro-
teins to initiate new protein synthesis [18]. In addition,
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another downstream molecule, known as eukaryotic initi-
ation factor 4E-binding protein 1 (4E-BP1), can be phos-
phorylated by mTOR on at least four sites [19,20]. Upon
phosphorylation 4E-BP1 (p-4E-BP1) permits the release of
eukaryotic translation initiation factor 4E (eIF4E) to asso-
ciate with eiF-4G, thereby facilitating the loading of the
ribosome onto the mRNA [21].
The mTOR-dependent mRNA translation pathway,
which can be specifically inhibited by rapamycin [22,23],
is one of the most important mechanisms that regulates
neuronal excitability and modulates long-term plasticity
associated with learning and memory [24-26]. Since syn-
aptic plasticity is responsible for central sensitization in-
duced by noxious stimuli in the CNS [27,28], it may
suggest that the mTOR pathway is essential to chronic
pain. Although it remains less clear if low levels of acti-
vated mTOR is sufficient to mediate acute pain in nor-
mal conditions [29], increasingly studies reveal that
mTOR-dependent signaling cascades are involved in
pain hypersensitivity [30,31].
However, the current knowledge regarding the linkage
between the mTOR-dependent pathway and pain-related
behaviors attributed to scorpion envenomation requires
further research. In this study, the following questions of
interest were investigated: 1) does the level of activated
mTOR and its respective downstream molecules change
under BmK I-induced pain state? 2) What is the distri-
bution of p-mTOR and its downstream molecules? 3)
Does the inhibition of spinal mTOR activity attenuate
BmK I-induced pain? and if so, 4) in which phase does
the mTOR-dependent pathway take effect?
Materials and Methods
Experimental animals
Adult male Sprague–Dawley rats (220 to 250 g; Shanghai
Experimental Animal Center, Chinese Academy of Sci-
ences) were housed under a 12-h light–dark cycle at
21–23°C with 50% humidity. Each cage contains five
rats with water and food available ad libitum. The rats
were habituated to the laboratory 5 days before experi-
ments. All procedures and testing occurred during the
light cycle. European Community guidelines for the
use of experimental animals and guidelines of Inter-
national Association for the Study of Pain (IASP) for
pain research in conscious animals were applied [32].
BmK I preparation and administration
The crude BmK venom collected by electrical stimula-
tion was purchased from an individual scorpion culture
farm in Henan Province, China. BmK I was purified
according to our previously described protocol [33]. The
purity of BmK I used in this study was assessed to be a
single peak on mass spectrum. BmK I was dissolved in
physiological saline (0.9% NaCl). 50 μl diluted BmK I
solution (0.2 μg/μl) and i.pl. injected into the left hind
paw of the animal.
Drugs
Rapamycin (TOCRIS bioscience, MO), the specific in-
hibitor of mTOR, was dissolved in saline/DMSO mix
comprising 25% v/v DMSO [30]. CCI-779 (Selleck
Chemicals LLC, TX) was prepared in pure ethanol as a
stock solution on the day of the experiment and diluted
to 250 μM in 0.15 M NaCl, 5% polyethylene glycol 400,
5% Tween 20 [34]. A volume of 10 μl of drug solution,
or equivolume vehicle, was injected intrathecally (i.t.) by
direct lumbar puncture between the L5 and L6 in rats
30 min before or 2 h after the i.pl. administration of
BmK I (n=8 for each group) as the previous description
[35]. Briefly, rats were slightly anesthetized with ether.
The i.t. injection was made with a 27-gauge, 1-inch ster-
ile disposable needle connected to a 25 μl Hamilton syr-
inge. Puncture of the dura was indicated by a reflexive
flick of tail or formation of an "S" by the tail.
Behavioral testing
Measurement of spontaneous response behaviors
A 20 × 20 × 30 cm3 transparent plexiglas box with a
glass floor was fixed on a steel frame of 75 cm high
above the experimental table covered with a mirror. Rats
were placed in the boxes for habituation at least 30 min
before the tests. After i.t. injection of rapamycin or ve-
hicle, rats were allowed to recover from anesthesia for a
short period of time. Subsequently, BmK I was subcuta-
neously injected in the left hind paw of rats at 30 min
post-rapamycin treatment. The behaviors are determined
by counting the number of flinches and the time dur-
ation spent in lifting and licking the injected hind paw
during a 5 min interval for 2 h [36]. Following the obser-
vation of spontaneous behaviors exhibited by the rats,
each experimental group (n=8) was examined for the
sensitivity to mechanical or radiated heat stimuli.
Measurement of paw withdrawal mechanical threshold (PWMT)
Rats were placed in a plexiglas test box (20 × 20 × 30 cm)
on a mesh floor (1 cm2 quadrate openings) for habitu-
ation 30 min before examination. Mechanical sensitivity
was assayed by using a series of 10 calibrated von Frey
filaments with forces from 0.6 to 26 g (58011, Stoelting
Co., IL). Filaments were applied from underneath the
metal mesh floor to the bilateral hind paws. Each fila-
ment was probed for the same duration of 2–3 s with an
inter-stimulus interval of 10 s. The positive response is
indicated by brisk withdrawal or flinching of the tested
paw. The rat PWMT was defined as the lowest force that
caused at least five withdrawals out of the ten consecutive
applications [36]. One day before experiment, the rats’
PWMTs were measured as the baseline value.
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Measurement of paw withdrawal thermal latency (PWTL)
Rat paw withdrawal thermal latency (PWTL) to radiant
heat stimuli was determined as previously described
[37]. Briefly, rats were placed on the surface of a 2 mm
thick glass plate covered with the transparent plexiglas
test box (20 × 20 × 30 cm3) for habituation at least 30
min before testing. Heat stimuli were provided with ra-
diant heat stimulator (RTY-3, Xi’an Fenglan instrumental
factory, China). The heat source was a high intensity
projector halogen lamp bulb (150 W, 24 V) positioned
under the glass floor 2 cm directly beneath the targeting
area of hind paw. The diameter of the light spot on the
floor surface was approximately 3 mm and an exposure
time of 20 s was set to limit tissue injury. For each rat,
five stimuli were administered and the stimuli interval
was 10 min. Rat PWTL was determined by averaging the
three middle values. One day before the experiment, the
rat PWTLs were collected as baseline values.
Moreover, those who were responsible for data collec-
tion were blind to the treatment.
Immunohistochemistry
Our previous study showed that the expression of c-fos,
a marker recognized as neuronal excitability, reached
the peak in rat spinal cord dorsal horn 2 h after BmK I
administration [13]. Consequently, we chose the time
point of 2 h to detect whether mTOR cascades were ac-
tivated through immunohistochemistry assay.
Figure 1 Immunoreactivity of p-mTOR in the spinal cord dorsal horn after intraplantar BmK I injection. Compared with the saline group
(A, B), BmK I treated groups (C-F) showed obvious immunoreactivity of p-mTOR in both ipsi- and contralateral spinal cord dorsal horn.
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Rats were anesthetized at time point of 2 h with pento-
barbital sodium (60 mg/kg body weight) and perfused
intracardially with 200 ml of sterile saline, followed by
400 ml of fixative containing 4% paraformaldehyde in
0.1 M phosphate buffer (PB; pH 7.4). The lumbar spinal
cord was dissected and post-fixed in the same fixative for
12 hours at 4°C and then cryoprotected in 0.1 M PB
containing 30% sucrose until the tissue sank to the bottom
of the container. Frozen serial coronal sections (14 μm in
thickness) were cut with a Microm cryostat (HM 525) and
mounted on gelatin-coated glass slides. Nonspecific bind-
ing was blocked by incubation with 5% normal horse
serum (S2000; Vector Laboratories, CA) in PBS with 0.3%
Triton X-100.
For double labeling of p-mTOR/p-p70 S6K/p-4E-BP1
with NeuN/GFAP/Iba-1, L5 spinal cord sections were in-
cubated for 48 h at 4°C with a mixture of rabbit mono-
clonal anti-p-mTOR (Ser2448 49F9, 1:200; #2976; Cell
Signaling Technology, MA [38])/rabbit polyclonal anti-
p-p70 S6K (Thr421/Ser424, 1:50; sc-7984-R; Santa Cruz,
CA)/rabbit monoclonal anti-p-4E-BP1 (Thr36, 1:50;
BS5047; Bioworld Technology, MN) and mouse monoclo-
nal anti-NeuN (clone A60, 1:600; MAB377; Millipore Bio-
science Research Reagents [31])/anti-GFAP (GA5, 1:200;
#3670; Cell Signaling Technology, MA)/goat polyclonal
anti-Iba-1 (1:50; ab5076; abcam, MA [39]). After rinsing
with 0.01 M PBS for 15 min, the sections were then incu-
bated with a mixture of donkey anti-rabbit IgG conjugated
Figure 2 4E-BP1 is phosphorylated in the spinal cord dorsal horn after intraplantar BmK I injection. Compared with the saline group
(A, B), BmK I treated groups (C-F) showed obvious immunoreactivity of p-4E-BP1 in both ipsi- and contralateral spinal cord dorsal horn.
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with Cy3 (1:500; 711-165-152; Jackson ImmunoResearch,
PA) and anti-mouse IgG conjugated with FITC (1:200;
715-095-020; Jackson ImmunoResearch, PA)/anti-goat
IgG conjugated with FITC (1:200; 705-095-003; Jackson
ImmunoResearch, PA) for 6 h at room temperature. Con-
trol experiments were performed in parallel. For detection
of p-mTOR/p-p70 S6K/p-4E-BP1, the sections were incu-
bated with a one of the previously mentioned antibodies
at 4°C for 48 h and then washed in 0.01 M PBS for 15 min.
Subsequently sections were then incubated with their re-
spective secondary antibodies conjugated with Cy3 or
FITC. After the sections were rinsed in 0.01 M PBS, cover
slips were applied. In order to exclude the potential
false-positive results arising from antibody selection,
the immunostaining results of p-mTOR, p-4E-BP1 and
p-p70 S6K were independently validated by other differ-
ent antibodies: anti-p-mTOR (Ser2448) antibody (#2971,
Cell Signaling Technology), anti-p-4E-BP1 (Thr37/46)
Rabbit mAb (#2855, Cell Signaling Technology) and anti-
p-p70 S6 Kinase (Thr421/Ser424) antibody (#9204, Cell
Signaling Technology). Related results could be found in
supplementary material (Additional file 1: Figure S2,
Additional file 2: Figure S3, Additional file 3: Figure S4).
All immunofluorescence-labeled sections were viewed
and captured with an Olympus FV-1000 confocal system
using sequential scanning to avoid fluorescence bleed-
through. Double-labeled images were quantitatively evalu-
ated with image analysis software (Image-Pro Plus 6.0).
Figure 3 Immunoreactivity of p-p70 S6K in the spinal cord dorsal horn after intraplantar BmK I injection. Compared with the saline
group (A, B), the immunoreactivity of p-p70 S6K in both sides of spinal cord dorsal horn increased significantly in BmK I treated groups (C-F).
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Figure 4 (See legend on next page.)
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Area frequency of co-labeled cells in mTOR cascades posi-
tive cells was analyzed. The threshold of positive signals
against noise signal or background was defined as shown
in supplementary figure (Additional file 4: Figure S1 A-D).
Intensities exceeding the threshold were accepted as
true immunostaining. Three homolographic fields cap-
tured from lamina III-V were measured (Additional file 4:
Figure S1 E). The average area in the three defined fields
presents the immunoreaction level. Three rats were used
for each group.
Protein extraction and immunoblotting
Rats were anesthetized with intraperitoneal injection of
sodium pentobarbital (60 mg/kg, i.pl.) and decapitated at
various time points after the BmK I administration. The
spinal cord of each rat was removed by pressure expulsion
with saline into an ice-cooled glass dish where the lumbo-
sacral enlargement was identified. Next, the section was
labeled and snap-frozen in liquid nitrogen until further
treatment. The sectioned tissues were homogenized
at 4°C in radioimmune precipitation buffer [150 mM
(See figure on previous page.)
Figure 4 BmK I-induced changes in spinal levels of p-mTOR, p-4E-BP1 and p-p70 S6K assessed by Western blot. (A) & (F), representative
western blots showing levels of p-mTOR, p-4E-BP, p-p70 S6K, total mTOR and β-actin in both ipsi- (A) and contralateral (B) side of the spinal cord.
(B-E) & (G-J), histograms represent the mean levels with respect to each control group at different time points after intraplantar BmK I injection.
The data are presented as mean ± S.E.M. of three rats per group. *p<0.05, **p<0.01, ***p<0.001, compared with control group by One-way
ANOVA, followed by Bonferroni's post hoc test.
Figure 5 Cellular localization of p-mTOR immunoreactivity in the spinal cord dorsal horn. (A-I) Cell-type-specific immunolabeling of
p-mTOR in the ipsilateral dorsal horn at 2 h after intraplantar BmK I injection. Arrows indicate colocalization of the p-mTOR (red) with the
respective cell markers (green). (J) Histogram of the cellular distribution of p-mTOR.
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NaCl, 100 mM Tris (pH 8.0), 1% Triton X-100, 1%
deoxycholic acid, 0.1% SDS, 5 mM EDTA and 10 mM
NaF] supplemented with 1 mM sodium vanadate, 2 mM
leupeptin, 2 mM aprotinin, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM DTT, and 2 mM pepstatin A. After
centrifugation at 14,000 rpm for 15 min, the supernatant
which contained the total cellular protein extract was col-
lected and stored at −70°C. The protein concentration was
determined using the Brandford assay (Sigma, MO).
Western blotting experiments were performed in
order to confirm the temporal phosphorylation level
of p-mTOR/p-p70 S6K/p-4E-BP1 following BmK I
administration. Briefly, thirty micrograms of protein
extracts were separated by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), and transferred to a
PVDF membrane. Nonspecific binding was blocked by
incubation in 5% nonfat milk overnight at 4°C. The
membranes were incubated with the following primary
antibodies which were diluted in PBS-T containing 5%
nonfat milk for 5 h at room temperature: rabbit poly-
clonal antibody against p-mTOR (Ser2448, 1:1000; #2971;
Cell Signaling Technology, MA [31])/rabbit monoclo-
nal antibody against mTOR (7C10, 1:1200; #2983; Cell
Signaling Technology, MA)/rabbit polyclonal antibody
against p-p70 S6K (Thr421/Ser424, 1:1500; sc-7984-R;
Santa Cruz, CA [40])/rabbit monoclonal antibody against
p-4E-BP1 (Thr37/46, 1:1000; #2855; Cell Signaling Tech-
nology, MA)/rabbit polyclonal antibody against Actin
(I-19, 1:1000; sc-1616; Santa Cruz, CA). The mem-
branes were then incubated with horseradish peroxidase-
conjugated secondary antibodies (1:10000; KC-RB-035;
KangCheng Biotechnology, China) for 2 h at room tem-
perature. Immunoblotting signals were visualized by
treatment with ECL reagent (WBKLS0050; Millipore
Bioscience Research Reagents) and exposed to film.
The bands were captured with the image analysis system
Figure 6 Cellular localization of p-4E-BP1 immunoreactivity in the spinal cord dorsal horn. (A-I) Cell-type-specific immunolabeling of
p-4E-BP1 in the ipsilateral dorsal horn at 2 h after intraplantar BmK I. Arrows indicate colocalization (yellow) of the p-4E-BP1 (red) with the
respective cell markers (green). (J) Statistical histogram of the cellular distribution of p-4E-BP1.
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and quantified using Quantity One software (Bio-Red
laboratory). All bands were normalized relative to the
corresponding β-actin band.
Inevitably, the antibody against p-4E-BP1 (#2855; Cell
Signaling Technology, MA) may cross-react with 4E-BP2
and 4E-BP3 when phosphorylated at equivalent sites.
All histochemical and blotting data were calculated by
an observer blind for treatment.
Statistical analysis
All results were expressed as mean ± S.E.M. (standard
error of the mean). Data of spontaneous response
behaviors and western blots between each groups were
compared by Owo-way ANOVA followed by a Bonferroni’s
post hoc test. Two-way ANOVA followed by a Bonferroni’s
post hoc test was used to analyze the effect of rapamycin or
CCI-779 on the PWTL and PWMT values after BmK I
administration.
Results
Unilateral injection of BmK I activates mTOR, p70 S6K and
4E-BP1 in bilateral spinal cord dorsal horn
Immunostaining was performed to evaluate whether the
level of phosphorylated mTOR, p70 S6K and 4E-BP1 had
changed following BmK I administration. In saline injected
rats, the intensity of p-mTOR immunostaining in the spinal
cord was low (Figure 1A-B). Two hours following BmK I
injection, p-mTOR-immunoreactive cells were detected in
abundance on both sides of the spinal cord dorsal horn.
The p-mTOR labeled cells was observed in all dorsal horn
laminas, particularly in the deep layers (lamina IV–VI)
(Figure 1C-F). Levels of mTOR, p-4E-BP1 and p-p70
S6K showed similar trends. After BmK I administration,
p-4E-BP1 reactivity increased in the superficial layers
(Lamina I-II) and deep layers (Lamina IV-VI) (Figure 2),
meanwhile p-p70 S6K positive signals increased markedly
in all laminas of the spinal cord dorsal horn (Figure 3).
Figure 7 Cellular localization of p-p70 S6K immunoreactivity in the ipsilateral spinal cord dorsal horn. (A-I) Cell-type-specific
immunolabeling of p-p70 S6K in the ipsilateral dorsal horn at 2 h after intraplantar BmK I. Arrows indicate colocalization (yellow) of the p-p70 S6K
(red) with the respective cell markers (green). (J) Statistical histogram of the cellular distribution of p-p70 S6K.
Jiang et al. Molecular Pain 2013, 9:50 Page 9 of 20
http://www.molecularpain.com/content/9/1/50
Figure 8 (See legend on next page.)
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In addition, western blotting experiments were per-
formed to confirm the immunostaining results. In naive
rats, limited activation of mTOR, as well as 4E-BP1 and
p70 S6K, was found on each side of the spinal cord. In
response to BmK I injection, the amount of p-mTOR
on the injured side increased rapidly and then peaked at
2 h (Figure 4B). The quantity of p-p70 S6K and p-4E-BP1
was noted to rise as well and returned to baseline at 1 day
(Figure 4C-D). Compared to the ipsilateral side, a slighter
but notable activation of the above molecules was ob-
served in the contralateral side (Figure 4F-I). The total
amount of mTOR was not affected by BmK I treatment
(Figure 4E and J).
Cellular localization of phosphorylated mTOR, p70 S6K
and 4E-BP1 in spinal cord dorsal horn
In order to determine which types of spinal cells were in-
volved in mTOR-mediated pain-related behaviors induced
by BmK I, double-label immunohistochemical staining
was performed.
Confocal microphotography revealed that 74.5 ± 4.2%
p-mTOR immunostaining positive profiles were co-localized
(See figure on previous page.)
Figure 8 Suppression effect of rapamycin on BmK I-induced rat pain behaviors. (A) Rat flinch behavior was attenuated when rats were
pre-treated with rapamycin (20 μM, 200 μM and 2 mM) 30 min before BmK I administration. Suppression of total number of the rat paw flinches
(B) and total number of paroxysmal pain-like behaviors (C) by rapamycin (20 μM, 200 μM and 2 mM) during 2 h after BmK I injection.
Suppression effect on ipsilateral (E) and contralateral (F) mechanical hypersensitivity, and ipsilateral (G) thermal hypersensitivity by different doses
of rapamycin pre-treatment (20 μM, 200 μM and 2 mM). However, rapamycin did NOT affect the lifting and licking behaviors (D) and the
contralateral basal thermal threshold value (H). *p<0.05, **p<0.01, ***p<0.001, compared with BmK I group; #p<0.05, ##p<0.01, ###p<0.001,
compared with DMSO vehicle group. n=8 for each group.
Table 1 The No. of rat flinch behavior in respective groups
BmK I BmK I+25%DMSO BmK I+20 μM RAPA BmK I+200 μM RAPA BmK I+2 mM RAPA
5 min 62.8±6.0 61.4±5.3 49.8±2.8 52.6±4.8 48.9±3.7
10 min 59.7±3.6 65.6±7.2 41.8±3.0 # 37.0±4.0 *, ## 44.8±5.2 #
15 min 59.3±3.6 62.1±5.7 39.0±5.0 # 43.9±6.6 39.9±5.8
20 min 58.6±5.0 64.9±6.1 35.8±4.0 **, ## 37.3±5.2 *, ## 39.5±3.7 *, ##
25 min 65.1±6.1 63.5±6.0 39.1±5.2 **, # 44.3±5.0 38.4±4.5 **, #
30 min 62.3±6.9 67.4±5.5 39.9±5.1 39.1±2.8 # 42.4±7.4 #
35 min 63.0±4.4 68.9±4.8 35.1±3.5 ***, ### 41.0±1.5 *, ### 38.6±6.2 **, ###
40 min 67.7±7.0 70.8±3.3 37.9±2.2 **, ### 38.0±4.0 **, ### 44.8±5.8 *, ##
45 min 61.6±6.2 69.9±5.0 38.9±2.4 **, ### 32.1±3.1 ***, ### 37.6±5.4 **, ###
50 min 70.9±6.7 66.8±6.1 37.1±3.1 **, ## 31.1±4.8 ***, ### 41.9±6.7 *, #
55 min 62.7±5.7 65.5±4.7 38.3±4.4 **, ## 33.3±6.1 ***, ### 40.8±3.0 *, #
60 min 63.1±6.3 56.0±6.3 43.5±1.8 29.4±4.6 ***, ## 44.0±4.3
65 min 57.0±7.2 47.4±3.6 43.3±2.8 26.3±4.8 **, # 39.6±5.1
70 min 53.4±2.8 47.8±3.9 39.1±4.3 31.8±3.7 * 32.3±5.2 *
75 min 45.0±2.0 52.1±4.5 37.6±4.0 29.9±3.5 *, ### 31.4±2.8 *, ##
80 min 50.0±6.2 51.6±6.3 38.4±5.4 31.0±5.2 **, ### 38.0±3.2
85 min 49.3±4.5 48.0±4.7 36.8±1.8 # 23.9±3.0 **, ### 33.8±3.8 #
90 min 48.9±5.2 55.0±4.6 33.5±4.0 22.1±5.0 33.9±4.2
95 min 46.4±1.8 40.6±5.9 37.5±5.0 26.0±5.3 29.3±4.8 *
100 min 43.4±5.3 42.1±7.0 36.6±3.5 29.0±3.0 24.3±4.2
105 min 39.0±2.7 40.0±6.9 31.8±3.5 28.1±4.0 31.6±6.3
110 min 31.7±4.4 36.1±5.5 31.8±2.6 24.6±2.7 27.1±5.4
115 min 26.6±2.8 37.6±5.3 29.5±3.3 30.6±3.4 24.8±5.2
120 min 30.1±5.6 33.5±6.3 29.8±3.8 21.8±3.9 21.1±5.2
Total 1258.8±76.7 1314.63±72.71 896.63 ± 44.46 **, ### 784.00 ± 48.79 ***, ### 868.38 ± 68.76 **,###
Note: *p<0.05, **p<0.01, ***p<0.001, compared with BmK I group. #p<0.05, ##p<0.01, ###p<0.001, compared with DMSO group.
One-way ANOVA followed by a Bonferroni's post hoc test.
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Table 2 Effect of rapamycin (pre-treatment) on mechanical and thermal hypersensitivity induced by BmK I
Paw withdrawal mechanical threshold (g) Paw withdrawal thermal latency (s)
Naive Vehicle Rapa Rapa Rapa Naive Vehicle Rapa Rapa Rapa
20 μM 200 μM 2 mM 20 μM 200 μM 2 mM
Ipsilateral
Base line 26.00 ± 0.00 26.00 ± 0.00 26.00 ± 0.00 26.00 ± 0.00 24.63 ± 1.38 12.74 ± 0.32 13.28 ± 0.38 12.60 ± 0.27 12.26 ± 0.24 12.66 ± 0.37
4 h 2.625 ± 0.42 1.80 ± 0.32 4.25 ± 0.45 7.75 ± 0.80 ***, ### 10.25 ± 1.08 ***, ### 6.84 ± 0.26 6.38 ± 0.32 8.01 ± 0.27 # 10.13 ± 0.23 ***, ### 11.24 ± 0.51 ***, ###
8 h 2.18 ± 0.27 1.8 ± 0.32 6.75 ± 0.53 ***, ### 8.5 ± 0.82 ***, ### 11.38 ± 2.35 ***, ### 6.62 ± 0.23 6.69 ± 0.29 9.39 ± 0.39 ***, ### 11.48 ± 0.55 ***, ### 12.06 ± 0.48 ***, ###
Contralateral
Base line 26.00 ± 0.00 26.00 ± 0.00 26.00 ± 0.00 26.00 ± 0.00 24.63 ± 1.38 12.10 ± 0.43 12.43 ± 0.26 13.09 ± 0.26 11.99 ± 0.23 13.28 ± 0.49
4 h 3.75 ± 0.70 2.25 ± 0.25 7 ± 0.53 15.63 ± 3.17 ***, ### 17.25 ± 3.38 ***, ### 12.9 ± 0.20 11.58 ± 0.23 12.26 ± 0.24 12.71 ± 0.37 12.69 ± 0.49
8 h 3.68 ± 0.50 2.50 ± 0.50 10.50 ± 1.10 *, ## 13.63 ± 2.03 ***, ### 17.88 ± 3.20 ***, ### 12.28 ± 0.33 11.78 ± 0.28 12.04 ± 0.29 12.79 ± 0.12 12.50 ± 0.23
Note: *p<0.05, **p<0.01, ***p<0.001, compared with BmK I group; #p<0.05, ##p<0.01, ###p<0.001, compared with vehicle group. Two-way ANOVA followed by a Bonferroni's post hoc test.
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with the neuronal marker NeuN in the dorsal horn
(Figure 5D-F). p-mTOR could be detected in only 9.8 ±
1.2% GFAP-positive astrocytes (Figure 5A-C) and 2.2 ±
0.7% Iba-1-positive microglia (Figure 5G-I).
Moreover, p-4E-BP1 was mainly observed in the spinal
neurons (87.2 ± 1.6%, Figure 6D-F) and only a few light
signals could be detected in astrocytes (3.4 ± 0.4%,
Figure 6A-C), but not in microglia (Figure 6G-I). The p-p70
S6K-positive cells were co-localized with spinal neurons (88.6 ±
5.3%, Figure 7D-F) but scarcely with microglia (Figure 7A-B).
Inhibiting spinal mTOR attenuates BmK I-induced rat
pain responses
Rapamycin and CCI-779, two specific inhibitors of
mTOR [23], were employed to investigate the potential
involvement of the mTOR pathway in BmK I-induced
pain-related behaviors.
Rapamycin or vehicle was i.t. injected at 30 min prior to
BmK I administration. Diluted DMSO, as vehicle, did not
affect BmK I-induced pain-related spontaneous behaviors
in rats. Compared with BmK I group or the vehicle group,
rapamycin (20 μM, 200 μM or 2 mM) suppressed the spon-
taneous flinching behaviors significantly (Figure 8A,
Table 1). The suppression of rapamycin on flinches
lasted for at least 90 min. Pre-treatment with rapamycin
at doses of 20 μM, 200 μM and 2 mM decreased
the total number of flinches and the number of paroxysmal
pain-like behaviors induced by BmK I within 2 h (Figure 8B-
C). However, the time duration of lifting and licking
behaviors was not affected by rapamycin (Figure 8D). Fur-
thermore, BmK I-induced hypersensitivity is influenced by
rapamycin. Bilateral mechanical hypersensitivity and ipsi-
lateral thermal hypersensitivity were dose-dependently
suppressed by pre-treatment with rapamycin at the time
point of 4 h and 8 h (Figure 8E-G, Table 2).
Western blots revealed a significant inhibition of 200
μM rapamycin on mTOR cascades in dorsal spinal cord
compared with vehicle and saline (Figure 9). I.t. rapamycin
not only decreased the activation of p-mTOR (Figure 9B
& G) in both sides, but also p-4E-BP1 (Figure 9C & H)
and p-p70 S6K (Figure 9D & I). The total amount of
mTOR was not affected by rapamycin.
Likewise, CCI-779 showed remarkable inhibitory effect
on BmK I-induced spontaneous responses (Figure 10A-C)
and hypersensitivity (Figure 10E-G, Table 3). A 250 μM
CCI-779 pre-treatment decreased the total number of
flinches (Figure. 10B) and the number of paroxysmal pain-
like behaviors (Figure 10C) within 2 h, inhibited BmK I-
induced bilateral mechanical hypersensitivity and ipsilateral
thermal hypersensitivity efficiently (Figure 10E-H, Table 3).
As well, CCI-779 was incapable of suppressing lifting and
licking behaviors (Figure 10D).
Post-treatment with rapamycin attenuate BmK I-induced
hyperalgesia
Post-treatment with rapamycin was also found to be
able to attenuate BmK I-induced hypersensitivity. Bilat-
eral mechanical hypersensitivity and unilateral thermal
hypersensitivity could be suppressed by post-treatment
with rapamycin (20 μM, 200 μM and 2 mM) signifi-
cantly (Figure 11A-C, Table 4). Neither pre- nor post-
treatment of rapamycin altered the contralateral basal
PWTL values (Figure 9H; Figure 11D).
Discussion
The localization of mTOR cascades in the spinal cord
under pain condition
In the physiological condition, the level of phosphorylated
mTOR, 4E-BP1/2 and p70 S6K were extremely low and they
were only detected in spinal cord dorsal horn neurons, but
not in astrocytes or microglia [29]. In the present study, we
found that the level of phosphorylated mTOR, p70 S6K and
4E-BP1 increased significantly following BmK I injection,
which were predominantly observed in spinal neurons.
Nevertheless, a small amount of positive signals were detected
in astrocyte (Figure 5–7). This result is consistent with previ-
ous reports from the formalin test and carrageenan-induced
pain model, where it was observed that p-mTOR and p-4E-
BP1 exist in spinal neurons and astrocytes [31].
Astrocytes are believed to contribute to the maintenance
of chronic pain since the activation of astrocytes is delayed
under conditions of peripheral injury [41,42]. In our previous
studies, astrocytes were demonstrated to contribute to BmK
sting-induced nociceptive behaviors. The activation of astro-
cytes in bilateral spinal cord initiated from day 3, peaked at
day 7 following i.pl. injection of BmK venom [43]. Although
there is still no direct evidence on the relationship between
pain processing and mTOR activation in spinal glia, some
studies have discovered valuable information. Codeluppi
et al. found that mTOR might mediate the astrocytic inflam-
matory reaction after nerve injury [44]. Tezel et al. recently
reported that, accompanying the development of inflamma-
tory responses induced by experimental glaucoma, mTOR
signaling pathway was activated [45]. Integrating these
(See figure on previous page.)
Figure 9 200 μM rapamycin inhibited the activation of spinal mTOR, 4E-BP1 and p70 S6K assessed by Western blot. (A) & (F),
representative western blots showing levels of p-mTOR, p-4E-BP, p-p70 S6K, total mTOR and β-actin in ipsi- (A) and contralateral (B) side of the
spinal cord. (B-E) & (G-J), histograms represent the mean levels with respect to each saline-treated group at 2 h after i.pl. BmK I injection. The
data are presented as mean ± S.E.M. of three rats per group. N.s., **p<0.01, ***p<0.001, compared with saline-treated group by One-way ANOVA,
followed by Bonferroni's post hoc test.
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investigation, whether we can approach a supposition that
the astroglial activation of mTOR pathway contribute to
the neuronal sensitization via control the release of inflam-
matory factors? It needs further demonstration.
In BmK I-induced pain, we did not find high amounts
of p-p70 S6K was co-labeled with glial cells. Moreover,
capsaicin and carrageenan induced activation of S6 pro-
tein (the substrate of p70 S6K) was found primarily in
spinal neurons but not glial cells, which is confirmed by
the results presented [46,47]. However, in some studies
carrageenan ignited spinal p-S6 was also detected in
microglia [31]. In fact, carrageenan induced microglial
activation of S6 is beyond overlapped with p-mTOR and
the co-labeling of p-S6 and microglia was extremely few.
This may suggest the existence of other signaling path-
ways other than mTOR/p70 S6K that can result in phos-
phorylated S6 and indicate that whether p70 S6K or S6
protein was activated in microglia is irrelevant to the de-
velopment of pain sensation. Also, the early activation of
downstream components before mTOR activation might be
owing to the intracellular pathways, including ERK1/2, PKB
and PKC. Shin et al. found that glycogen synthase kinase
(GSK)-3 was another up-stream modulator of p70 S6K
except mTOR [48]. Even so, mTOR could be still served
as the predominant modulator while other factors might
play minor roles. It could be verified by the pharma-
cological and behavioral tests: pre-administration of rapa-
mycin, the specific inhibitor of mTOR, significantly
suppressed the activation of mTOR, as well as p70 S6K
and 4E-BP1 (Figure 9), which attenuating pain-related be-
haviors accordingly (Figure 8).
The activation of mTOR cascades in different animal
pain models
Although, most of previous studies supported the view that
mTOR cascades were involved in pain sensation, the opin-
ion was still conflicting regarding to the activation modes
in different animal models. Géranton et al. reported that ac-
tivated mTOR in SNI model was found in a subpopulation
of A-fiber dorsal root ganglion neurons and in spinal lam-
ina I/III projection neurons [46], while Asante et al. found
activated mTOR pathway components in some C-fiber dor-
sal root ganglion neurons and in spinal lamina II interneu-
rons [49]. Here we mimicked a scorpion stinging-induced
chronic pain state through employment of BmK I. Acti-
vated mTOR and its downstream components could be
found in all spinal laminae in the model. Moreover, another
recent study suggested that p-mTOR was co-labeled with
61.3±1.8% CGRP-positive C-fiber neurons, 64.6%±1.2%
IB4-positive C-fiber neurons and 42.4%±1.2% NF200-
positive A-fiber neurons in dorsal root ganglion after BmK
I administration (unpublished data). Hence, it allowed us to
infer that the varied activation pattern of mTOR cascades
might be owing to the different animal models used.
The rapid behavioral anti-nociceptive effect of
rapamycin / CCI-779
As with previous studies [30,31], a rapid anti-nociceptive
effect of rapamycin on pain-related spontaneous behav-
iors was observed in the BmK I-induced pain model. The
total number of flinches, paroxysmal pain-like behaviors
and long-term pain hypersensitivity were significantly
decreased following rapamycin/CCI-779 administration.
(See figure on previous page.)
Figure 10 Suppression effect of CCI-779 on BmK I-induced rat pain behaviors. (A) Rat flinch behavior was attenuated when rats were pre-
treated with CCI-779 (250 μM) 30 min before BmK I administration. Suppression of total number of the rat paw flinches (B) and total number of
paroxysmal pain-like behaviors (C) by CCI-779 during 2 h after BmK I injection. (D) No effects on lifting and licking behaviors. Suppression on
ipsilateral (E) and contralateral (F) mechanical, and ipsilateral thermal (G) hypersensitivity by CCI-779, but no effect on contralateral basal thermal
threshold value (H). *p<0.05, **p<0.01, ***p<0.001, compared with BmK I group. #p<0.05, ##p<0.01, ###p<0.001, compared with vehicle group.
n=8 for each group.
Table 3 Effect of CCI-779 (pre-treatment) on mechanical and thermal hypersensitivity induced by BmK I
Paw withdrawal mechanical threshold (g) Paw withdrawal thermal latency (s)
Naïve Vehicle CCI-779 Naïve Vehicle CCI-779
Ipsilateral
Base line 26.00 ± 0.00 26.00 ± 0.00 26.00 ± 0.00 12.74 ± 0.40 13.64 ± 0.23 13.55 ± 0.44
4 h 2.63 ± 0.42 1.88 ± 0.36 6.50 ± 0.73 ***, ### 6.84 ± 0.35 7.75 ± 0.26 9.64 ± 0.35 ***, ###
8 h 2.18 ± 0.27 3.25 ± 0.62 8.88 ± 1.16 ***, ### 6.62 ± 0.28 7.43 ± 0.30 10.99 ± 0.37 ***, ###
Contralateral
Base line 26.00 ± 0.00 26.00 ± 0.00 24.63 ± 1.38 12.10 ± 0.50 13.28 ± 0.37 13.69 ± 0.44
4 h 3.75 ± 0.70 2.35 ± 0.37 12.00 ± 1.17 ***, ### 12.90 ± 0.27 13.71 ± 0.39 12.95 ± 0.61
8 h 3.68 ± 0.50 4.25 ± 0.70 17.63 ± 2.61 ***, ### 12.28 ± 0.45 13.36 ± 0.53 12.61 ± 0.35
Note: ***p<0.001, compared with BmK I group; ###p<0.001, compared with cehicle group. Two-way ANOVA, Bonferroni's post hoc test.
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In the current study rapamycin (CCI-779 as well) has no
effect on lifting and licking behavior induced by BmK I,
whereas rapamycin significantly attenuated licking and bit-
ing but not on lifting and flinching elicited by formalin [30].
The seemingly diverse effects of rapamycin/CCI-779 might
depend on the distinct characteristic of animal pain models.
In the formalin test, the duration of licking behavior is
greater than that of lifting. However, rats injected with
BmK I spend more time on lifting but little time on biting
and licking the injured hind paw. In summary, due to the
absence of an effect on lifting behavior, mTOR inhibitors
are not suppressors of the total lifting and licking behavior
induced by BmK I.
The possible relationship between mTOR-dependent
signaling pathway and pain
Spinal synaptic plasticity is indispensable in the sen-
sitization to peripheral noxious stimuli and generation
of chronic pain [27]. Protein synthesis at the site of syn-
apse and soma is required for the formation of neuronal
Figure 11 Post-treatment with rapamycin suppressed unilateral thermal hypersensitivity and bilateral mechanical hypersensitivity
induced by intraplantar BmK I injection. (A and B) showed the suppressive effects on BmK I-induced the ipsilateral (A) and contralateral (B)
mechanical hypersensitivity by different doses of rapamycin post-treatment (20 μM, 200 μM and 2 mM). (C and D) showed that different doses of
rapamycin post-treatment (20 μM, 200 μM and 2 mM) suppressed ipsilateral (C) thermal hypersensitivity but did not affect the contralateral basal
thermal threshold value (D). **P<0.01, ***P<0.001, compared with relevant control groups treated with DMSO. n=8 for each group.
Table 4 Effect of rapamycin (post-treatment) on mechanical and thermal hypersensitivity induced by BmK I
Paw withdrawal mechanical threshold (g) Paw withdrawal thermal latency (s)
Vehicle Rapa Rapa Rapa Vehicle Rapa Rapa Rapa
20 μM 200 μM 2 mM 20 μM 200 μM 2 mM
Ipsilateral
Base line 26.00 ± 0.00 26.00 ± 0.00 24.63 ± 1.38 26.00 ± 0.00 12.59 ± 0.19 13.28 ± 0.25 13.30 ± 0.37 12.94 ± 0.27
4 h 1.80 ± 0.21 4.00 ± 0.89 4.00 ± 0.18 * 4.93 ± 0.56 ** 5.98 ± 0.36 9.21 ± 0.60 *** 9.83 ± 0.39 *** 8.86 ± 0.28 ***
8 h 2.13 ± 0.33 5.25 ± 1.08 ** 6.00 ± 0.35 *** 6.75 ± 0.62 *** 6.36 ± 0.31 9.61 ± 0.41 *** 9.55 ± 0.22 *** 9.38 ± 0.12 ***
Contralateral
Base line 26.00 ± 0.00 26.00 ± 0.00 24.63 ± 1.38 26.00 ± 0.00 12.43 ± 0.26 12.94 ± 0.23 12.36 ± 0.16 12.54 ± 0.24
4 h 2.50 ± 0.27 9.13 ± 0.83 *** 8.88 ± 0.74 *** 8.63 ± 0.81 *** 12.04 ± 0.42 12.94 ± 0.21 12.21 ± 0.34 12.03 ± 0.23
8 h 2.75 ± 0.40 10.00 ± 1.77 *** 10.38 ± 1.23 *** 8.38 ± 0.87 *** 12.11 ± 0.25 13.1 ± 0.35 13 ± 0.36 12.13 ± 0.21
Note: *p<0.05, **p<0.01, ***p<0.001, compared with relevant vehicle groups. Two-way ANOVA followed by a Bonferroni's post hoc test.
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plasticity [50,51]. Since the effects of mTOR on neuronal
synaptic plasticity are at least partly related to the phos-
phorylation of 4E-BP1 and p70 S6K [52-54], two vital regu-
lators of protein expression, it is reasonable to consider
mTOR as an incontrovertible candidate participating in the
modulation of nociceptive transmission in the central ner-
vous system. Moreover, mTOR activity has been demon-
strated to be necessary for the electric stimulation-evoked
late-phase long-term potentiation (L-LTP) and BDNF-
induced strengthening of synaptic transmission in acute
rodent hippocampal slices [55]. Agonists of metabotropic
glutamate receptors induced-LTD in hippocampal CA1
area could be blocked by rapamycin [56]. All the evidence
suggests mTOR signaling pathway is of vital importance to
the central plasticity. Behavioral testing has confirmed that
mTOR-dependent spinal mRNA translation is responsible
for formalin-induced spinal neuronal hyperexcitability and
carrageenan-induced behavioral hyperalagesia [30,47,57].
Apart from controlling protein synthesis, we have to note
that mTOR is implicated in multiple processes, including
ubiquitin-dependent proteolysis, microtubule and actin
dynamics, all of which are crucial for regulating synap-
tic strength [15].
Pre- and post-treatment with rapamycin decreased BmK
I-induced behavioral hypersensitivity
The administration method of a therapeutic agent/
molecule is a key factor of consideration. Clinically,
the post-treatment phase is more relevant. Pre- and
post-administration of rapamycin has shown excellent
anti-nociceptive effect on both electrophysiological
and behavioral studies in spared nerve injury (SNI)
and formalin model [31,46,49]. In our research, the anti-
nociceptive effect of pre- and post-treatment of rapamycin
were evaluated in BmK I-induced pain model. After pre-
treatment with rapamycin or CCI-779, the unilateral
thermal hypersensitivity and bilateral mechanical hy-
persensitivity were significantly suppressed. This sug-
gests that the mTOR signaling pathway mediates the
induction of pain behaviors induced by BmK-I. Furthermore,
rapamycin post-treatment also showed an effective anti-
hypersensitivity effect. Thus, it is demonstrated that the
mTOR-dependent signaling network was also involved in
the maintenance of BmK I-induced pain.
However, the contribution of mTOR signaling pathway
on thermal hyperalgesia is still controversial. While the
mTOR inhibitor CCI-779 has no effect on spinal nerve
ligation evoked thermal hypersensitivity [49], rapamycin
exerted a significant inhibition on the responses to thermal
stimuli in formalin and carrageenan-induced inflammatory
pain [30,47]. What’s more, under short term inflammation
pain state, nociceptive signals mediated by C-fiber and the
responses of WDR neurons to the peripheral input was
significantly inhibited by rapamycin [30]. In the present
study, both rapamycin and CCI-779 efficiently increased
the paw withdrawal thermal latency on BmK I-injected
rats. It is thus clear that the inhibitors of mTOR are in-
clined to weaken inflammation but not nerve damage-
induced thermal hypersensitivity. A possible determinant
for this phenomenon might be the distinctive genesis of
different animal models. Inflammatory pain is primarily
attributed to inflammatory factors released from the in-
flamed tissue. Whereas neuropathic pain generally orig-
inates from the pathology of the nervous system.
Neurogenic changes or injury leads to a steadier central
and peripheral sensitization than that in inflammatory
pain. Thus, the inhibitors of mTOR pathway are prob-
ably insufficient to weaken long term pathologic pain-
induced thermal hypersensitivity.
In combination with previous results, including elec-
trophysiological recording [7,58], behavioral observation
[10], amino acid neurotransmitter release [12] and c-Fos
expression in spinal cord dorsal horn [13], the potential
mechanisms of BmK I-induced pain would rely firstly on
the selective modulation of BmK I on voltage-gated so-
dium channels in the peripheral A and C primary affer-
ent fibers, transmitting pain signals into the spinal cord,
followed by an increase in spinal glutamate release and
the activation of the neuronal mTOR signaling network.
All these events lead to the elevated protein/peptides ex-
pression, and finally altered spinal plasticity.
Conclusion
In summary, this work revealed that mTOR signaling
pathway was dramatically activated on both sides of the
rat spinal cord in response to the peripheral injection of
BmK I. Both pre- and post-treatment of rapamycin
showed a remarkable inhibition on spinal mTOR activity,
and thereby displayed anti-nociceptive effect. The present
study suggested that the mTOR-dependent signaling path-
way, at least partially, contributes to BmK I-induced per-
sistent pain. The mTOR signaling pathway might be a
novel target to alleviate persistent and chronic pain.
Additional files
Additional file 1: Figure S2. Immunostaining of p-mTOR was performed
by using two individual antibodies from Cell Signaling Technology (CST,
antibody 1 catalog #2976, antibody 2 catalog #2971). A&B, animal received i.pl.
injection of saline and pre-administration of Rapamycin (i.t.). C&D, animal
received i.pl. injection of saline and pre-administration of saline (i.t.). E&F,
animal received i.pl. injection of BmK I and pre-administration of saline (i.t.).
G&H, animal received i.pl. injection of BmK I and pre-administration of
Rapamycin (i.t.).
Additional file 2: Figure S3. Immunostaining of p-4E-BP1 was
performed by using two individual antibodies: antibody 1 catalog BS5047
from Bioworld Technology and antibody 2 catalog #2855 from CST). A&B,
animal received i.pl. injection of saline and pre-administration of
Rapamycin (i.t.). C&D, animal received i.pl. injection of saline and pre-
administration of saline (i.t.). E&F, animal received i.pl. injection of BmK I
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and pre-administration of saline (i.t.). G&H, animal received i.pl. injection
of BmK I and pre-administration of Rapamycin (i.t.).
Additional file 3: Figure S4. Activated p70 S6K was stained by two
individual antibodies: antibody 1 catalog sc-7984-R from Santa Cruz and
antibody 2 catalog #9204 from CST). A&B, animal received i.pl. injection
of saline and pre-administration of Rapamycin (i.t.). C&D, animal received
i.pl. injection of saline and pre-administration of saline (i.t.). E&F, animal
received i.pl. injection of BmK I and pre-administration of saline (i.t.). G&H,
animal received i.pl. injection of BmK I and pre-administration of
Rapamycin (i.t.).
Additional file 4: Figure S1. Illustration of quantitative assessment of
double labeling staining. Selected (A) mTOR cascade positive
microphotograph and (C) double labeled microphotograph (the same
position as shown in A). (B) and (D) Software assisted evaluation of A & B:
blue regions were defined as positive signals. (E) The measuring area, as
well as the high magnified images in Figure 2, 3 and 4, was captured
from lamina III-V of L5 spinal cord dorsal horn.
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